Prepared by: Athina Oikonomidou

Bus Dev & Tech Transfer Consultant EkinisiLab/SEV

SME INSTRUMENT & FAST TRACK TO INNOVATION


03 November 201*5*

NCPs event on Horizon 2020
"Health, demographic change and well-being"

Outline

- ☐ SME Instrument
 - Key Features / Definitions
 - The evaluation process
 - The Good and the Bad
- Fast Track to Innovation
 - Key Features
 - SME Istrument vs FTI
- Conclusions


H2020 Health Programme



Societal Challenges

^{*} From the Presentation of Antoine Miahle, EU Health Policy Officer

H2020 Health Programme



Societal Challenges

SME Instrument

The SME Instrument Objectives

- Address the financing gap in developing highpotential, but high-risk innovative ideas of small companies and bringing them closer to the market
- Support highly innovative SMEs showing a strong ambition to develop, grow and internationalise

- Finding the small gold nugget:
 - SME's with strong growth potential
 - SME's with ambition to become world-market leader

ldea

ldea Market



Phase I

ldea

Concept & Feasibility Assessment

Market

- Feasibility of concept
- Risk assessment
- IP regime
- Partner search
- Design study

Phase I

ldea

Concept & Feasibility Assessment

Market

- Feasibility of concept
- Risk assessment
- IP regime
- Partner search
- Design study

€ 50.000

~ 6 months

Phase I

Concept & Demonstration,
 Market
 Assessment

Phase II

Demonstration,
 Market
 Replication, R&D

- Feasibility of concept
- Risk assessment
- IP regime
- Partner search
- Design study

€ 50.000 ~ 6 months

Phase I Phase II

Concept & Demonstration,

ldea

Feasibility
Assessment

Market
Replication, R&D

Market

- Feasibility of concept
- Risk assessment
- IP regime
- Partner search
- Design study

- Clinical trials
- Development, prototyping
- Miniaturisation, design
- Etc.

€ 50.000

~ 6 months

Phase I Phase II Concept & Demonstration, ldea Feasibility Market Replication, R&D Assessment Clinical trials Feasibility of Development, concept Risk assessment prototyping • IP regime Miniaturisation, Partner search design Design study • Etc. € 0,5 to 2,5 million (1 to 5)

Up to 36 months

70 % funding (100%

SMEIns-05)

€ 50.000

~ 6 months

Market

Phase I Phase II Phase III

Concept & Feasibility Assessment

Demonstration, Market Replication, R&D

Commercialization

Market

- Feasibility of concept
- Risk assessment
- IP regime
- Partner search
- Design study
 - € 50.000 ~ 6 months

- Clinical trials
- Development, prototyping
- Miniaturisation, design
- Etc.

```
€ 0,5 to 2,5 million (1 to 5)
Up to 36 months
70 % funding (100%
SMEIns-05)
```

Phase II Phase I Phase III Concept & Demonstration, ldea Market Commercialization Market Feasibility Replication, R&D Assessment Facilitate access to Clinical trials Feasibility of

- concept
- Risk assessment
- IP regime
- Partner search
- Design study

€ 50.000 ~ 6 months

- Development, prototyping
- Miniaturisation, design
- Etc.

€ 0,5 to 2,5 million (1 to 5) Up to 36 months **70 % funding (100%** SMEIns-05)

- private finance
- Support via
 - networking ,
 - training,
 - coaching,
 - knowledge sharing,
 - dissemination

Phase II Phase I Phase III Concept & Demonstration, ldea Market Commercialization Market Feasibility Replication, R&D Assessment Facilitate access to Clinical trials Feasibility of private finance Development, concept Risk assessment Support via prototyping

Design study

Partner search

• IP regime

€ 50.000 ~ 6 months

- Miniaturisation, design
- Etc.

€ 0,5 to 2,5 million (1 to 5)
Up to 36 months
70 % funding (100%
SMEIns-05)

- networking,
- training,
- coaching,
- knowledge sharing,
- dissemination

NO direct funding

Evaluator Guidelines

- □ TRL 6 is a must but not for SMEInst-05
 - TRL6: technology demonstrated in relevant environment (industrially relevant environment in the case of key enabling technologies)
- Ability of the Applicant to commercialize
 - Previous Track record
 - Experience & Expertise of Key personnel
- Subcontracting can only be a limited part of Phase II
- Costs should be realistic, reasonable and justifiable

Phase I – Phase II Differences

Pre-financing	40% of the Lump sum.	Fixed individually at the grant preparation level.
Technical Annex	Technical annex 1-3 (10 pages)	Technical annex 1-3 (30 pages)
Evaluation	Impact = 4	Impact = 4
thresholds	Excellence = 4	Excellence = 3
	Quality & efficiency of	Quality & efficiency of implementation = 3
	implementation = 4	Total = 12
	Total = 13	
Subcontracting	The applicant shall declare the tasks	Subcontracting may cover only a limited part of
	to subcontract.	the action.
	The subcontract is not included in the technical annex 2.	Can certain tasks of a clinical trial be subcontracted? Specialised services (pharmacokinetics, regulatory assistance etc.) might be indispensable for the implementation of the clinical trial. 'Academic providers' exist (e.g. the ECRIN network), but most of the suppliers are for-profit and the Commission will consider accepting subcontracting in these cases. If clinical trial just a small part of the action, it might even be subcontracted in its entirety.
Costs	It is not necessary to detail the estimated costs.	To check if costs are realistic, reasonable and justifiable.

Some Advice...

- Don't start a company just to make use of the SME Instrument
- Have a clear vision of what you want to do
- Describe what you plan to do with the money and what you will achieve
- Make sure you know what other people are doing
- Be concise, use the 10 (or 30) pages wisely...
- Collaborations can be key

Fast Track to Innovation

Key Features

- Allows consortia of min. 3, max. 5 members mandatory industry involvement
- Proposals shall include a business plan (market development strategy)
- Impact criterion has higher weighting in evaluations
- One common call, permanently open, 3 cut-offs per year
- Time-to-grant 6 months
- □ •Funds innovation actions (70%), grant up to €3 M

The Objectives

- Reduce time from idea to market Give that last push...
- Increase participation of industry, first-time applicants, SMEs
- Stimulate private sector investment in R&I

Industry Involvement

Industry-intensive consortia from EU or Associated Countries meaning:

- Either 2 out of 3-4 partners are "industry" (= private for profit)
- •Or 3 out of 5 partners are private for profit
- Or 60% of the budget (= total estimated eligible costs) is to be allocated to consortium partner(s) from industry

SMEs and first-time industry applicants particularly welcome.

Conclusions

FTI Pilot vs SME Instrument

- Target: FTI Pilot does not target SMEs exclusively nor does it allow single applicants to submit proposals. Industry intensive consortia is mandatory
- •Theme/topics: Only FTI is fully bottom-up; does not support specific topics and that applicants themselves can set the topic within the "Societal Challenges" and the "LEITs"
- Both instruments offer close-to-market support to speed up market delivery of innovation, but in the case of the FTI, the goal is the delivery of an innovation onto the market within a period of 36 months
- Subcontracting: general rules under H2020 apply to FTI: Subcontracting in the case of FTI Pilot is allowed but the core action must be in the partners
- A one-stage scheme helping industry-driven consortiums to mature and deliver advanced innovation concepts onto the market; no phases no coaching provided under this Pilot action.
- 70% funding vs 100% for Phase II PHC12 proposals

General Recommendations

- Focus on the application
- Learn the market
- Think big
- Choose your partners wisely
- □ Take time Review your proposal
- Use external experts wherever possible

Hoping more Greek companies take Advantage of the new Funding Tools

For any further clarifications athikonomidou@gmail.com